Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2025-01-02 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 December 2024
Regulatory Filings Classification · 87% confidence The document is the prescribed HKEX FF301 monthly return form under Chapter 19B of the Listing Rules, detailing movements in authorized/registered share capital, issued shares, share options, and confirmations under Main Board/GEM Rules. It is a routine regulatory submission rather than a financial report (e.g., Annual/Interim report), earnings release, or specific announcement like dividends or M&A. Therefore, it falls under general Regulatory Filings.
2025-01-02 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is a Hong Kong Stock Exchange Next Day Disclosure Return (Form FF305) detailing changes in issued shares, treasury shares, repurchase of shares, prices, aggregate amounts, and related dates. It is a mandatory regulatory report of the company buying back its own shares. This directly matches the “Transaction in Own Shares” category (share repurchase/issuance).
2024-12-31 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 85% confidence The document is a Next Day Disclosure Return (Form FF305) filed under HKEX listing rules detailing changes in issued shares and treasury shares, including share repurchases and holding as treasury shares. It reports on the company’s own share transactions (buybacks) with dates, quantities, prices, and compliance notes. This matches the definition of a “Transaction in Own Shares” filing.
2024-12-30 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is an FF305 “Next Day Disclosure Return” filed under Hong Kong Listing Rules, detailing changes in issued shares and treasury shares, specific share repurchase events (quantities, prices, dates), repurchase mandate details, and confirmation by the company secretary. It is clearly a report of the company buying back its own shares, matching the definition of “Transaction in Own Shares.” There is no discussion of dividends, M&A, board changes, or full financial results—only share buyback disclosure. Therefore, it should be classified as POS.
2024-12-27 English
VOLUNTARY ANNOUNCEMENT INDUSTRIAL LAND REFORM PROPOSAL
Regulatory Filings Classification · 82% confidence The document is a voluntary announcement by a Hong Kong-listed issuer regarding an industrial land reform proposal and investment project. It does not present financial results, board changes, fundraising, dividends, or other specific report content; nor does it attach or publish a formal report. It is a general regulatory announcement updating the market on a business development, fitting the fallback category for miscellaneous regulatory filings.
2024-12-20 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 93% confidence The document is a Hong Kong Stock Exchange “Next Day Disclosure Return” (Form FF305) for Ascletis Pharma Inc., detailing changes in issued shares and treasury shares, including on‐market share repurchases and treasury share sales. It provides quantitative details on share buybacks and treasury share movements. This aligns with the “Transaction in Own Shares” category, which covers reports of a company buying back or selling its own shares.
2024-12-20 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.